Publicly-traded company Collegium Pharmaceutical Inc. (NASDAQ:COLL) had a closing price of $18.00 yesterday. Meanwhile, the average 12-month price target from Wall Street analysts is currently $24.14, this means that the stock is underpriced by 25.43%. In the past 52 weeks the company’s stock price has moved within the range of $10.01 to $19.83.
This particular stock’s 5-day moving average is 14.33, its 20-day moving average is 12.54 and its 100-day moving average is 11.74. Collegium Pharmaceutical Inc. (COLL) currently has 33.40M shares outstanding, which means that its market capitalization is $601.16M.
The Details: Collegium Pharmaceutical Inc. (COLL) Financial Health
There are several indicators we can take into consideration when thinking about a stock’s financial health. For example, we can look at a company’s profit margin, which tells us how much of the company’s total sales revenue was kept in earnings. We calculate this figure by dividing net income by net sales revenue. COLL currently has a profit margin of -7.40%.
Looking at a company’s operating margin is also helpful. This number tells us how much profit is kept after considering depreciation and operating expenses. Collegium Pharmaceutical Inc. (COLL) has an operating margin of -5.20%.
Return on Assets, which is expressed as a percentage, tells us how well a public company is using its assets to turn a profit. The larger the percentage, the better it is At the moment, Collegium Pharmaceutical Inc. Return on Assets is -5.70%.
What Does Wall Street Say about Company?
When selecting potential stocks to buy, many investors want to find out what Wall Street professionals are thinking about the company beforehand – like what the average analyst rating is. At the moment, the average analyst rating for COLL is Buy. Out of 9 total analysts who were surveyed, 0 rated it a sell, 0 rated it a underweight, 0 rated it an overweight, 0 rated it hold, and 9 rated it a Buy.
Understanding Profitability at Collegium Pharmaceutical Inc. (COLL)
A good way of assessing a public company’s profitability is by looking at its Earnings per Share (EPS). In the most recent financial results released by Collegium Pharmaceutical Inc., for the quarter ending on 12/2019, the company posted EPS of -0.03. The average estimate of Wall Street analysts had projected 0.23.
Wall Street analysts, on average, are forecasting the company’s EPS to be -0.15, compared to 0.27 reported in the same quarter last year. When it comes to net revenue, the average estimate from a total of 8 analysts is 75.68M – compared to 73.43M posted in the year-ago period.